Octreoteva Long Acting (Octreotide)

Octreotide, the active ingredient in Octreoteva Long Acting, is a somatostatin analog presented as a long‑acting formulation for injectable use. It is employed in the management of hormone‑related tumors and certain gastrointestinal disorders in adult patients. GNH USA supplies Octreoteva Long Acting as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Octreotide is a synthetic somatostatin analogue that modulates neuroendocrine and gastrointestinal hormone pathways. - Acromegaly: reduces excess growth hormone secretion and controls disease activity. - Neuroendocrine tumors (carcinoid syndrome): alleviates flushing and diarrhoea associated with serotonin excess. - Severe diarrhea associated with vaso‑active intestinal peptide (VIP) tumours (VIPoma): decreases intestinal secretions and improves fluid balance.

Octreotide may cause a range of adverse reactions, most of which are mild to moderate and reversible.

Common Side Effects: - Gastrointestinal discomfort, including nausea, abdominal cramping and diarrhoea. - Injection‑site reactions such as pain, erythema or induration. - Gallbladder sludge or gallstones. - Hyperglycaemia or hypoglycaemia, reflecting altered insulin dynamics.

Serious or Rare Side Effects: - Severe hypersensitivity reactions, including anaphylaxis. - Acute pancreatitis. - Significant cardiac arrhythmias. - Profound electrolyte disturbances, particularly hyper‑ or hyponattrative ​  ​  ​  ​  ​  ​  ​  ​  ​  ​

Octreotide should be used under careful clinical supervision, with attention to patient‑specific factors and monitoring requirements. - Renal impairment: dose adjustment may be required in severe renal dysfunction. - Hepatic dysfunction: monitor liver enzymes and consider dose modification. - Glucose metabolism: monitor blood glucose regularly, especially in diabetic patients. - Gallbladder disease: assess risk of gallstone formation during long‑term therapy. - Pregnancy and lactation: evaluate risk‑benefit ratio; use only if clearly indicated. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octreotide may interact with several concomitant medicines, altering efficacy or safety.

Major Interactions (Avoid): - Cyclic      ​ ​  ​ ​  ​  ​  ​  ​  -        """"  "  """  """ "" """ "" "  "" " "" " "  "" " "  " "" "" "  "  " "  " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " "  -  

Moderate  -  -  -